trial

KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution

NCTId NCT06218979
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Helsinki University Central Hospital
Primary completion 2024-03-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2023-12-08
Primary completion
2024-03-14
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Helsinki University Central HospitalLead Sponsor
University of HelsinkiCollaborator

Investigators

1
Janne Backman, MD, PhDPrincipal Investigator

Sites

1 total
Helsinki, Finland

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2024-03-14
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Helsinki University Central Hospital
company
collaborator
University of Helsinki
company
indication
Psychosis
indication
Food-drug Interaction
indication
Psychotic Disorders
indication
investigator
Janne Backman, MD, PhD
person